[CAS NO. 114870-03-0] Fondaparinux Sodium (Org 31540)

Name: Fondaparinux Sodium (Org 31540)
Brand: Arctom Scientific
SKU: SLK-S3736

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [114870-03-0]

Store

Catalog

SLK-S3736

Brand

Selleck

CAS

114870-03-0

DESCRIPTION [114870-03-0]

Overview

MDL	MFCD06794972
Molecular Weight	1728.08
Molecular Formula	C31H43N3O49S8.10Na
SMILES	O([C@H]1[C@H](OS(=O)(=O)O)[C@@H](NS(=O)(=O)O)[C@@H](O[C@@H]2[C@H](C(O)=O)O[C@@H](O[C@@H]3[C@@H](COS(=O)(=O)O)O[C@H](OC)[C@H](NS(=O)(=O)O)[C@H]3O)[C@H](OS(=O)(=O)O)[C@H]2O)O[C@@H]1COS(=O)(=O)O)[C@@H]4O[C@H](C(O)=O)[C@@H](O[C@@H]5[C@H](NS(=O)(=O)O)[C@@H](O)[C@H](O)[C@@H](COS(=O)(=O)O)O5)[C@H](O)[C@H]4O.[Na]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	0.5787 mL	2.8934 mL	5.7868 mL
5 mM	0.1157 mL	0.5787 mL	1.1574 mL
10 mM	0.0579 mL	0.2893 mL	0.5787 mL
50 mM	0.0116 mL	0.0579 mL	0.1157 mL

Description

Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of .

Targets

Factor Xa ^[1]

In vitro

Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa (FXa) in the coagulation cascade. Fondaparinux has been shown to inhibit the TF-FVIIa complex and FIXa in vitro.

In vivo

Fondaparinux reduces kidney I/R injury primarily by inhibiting the recruitment of neutrophil. It dramatically reduced fibrin deposition in the kidney. Fondaparinux can promote the stability of atherosclerotic lesions in apolipoprotein E-deficient mice, possibly through inhibiting expression of the inflammatory mediators in plaque and reduced synthesis of MMP-9 and MMP-13.

References

[1] Frank RD, et al. J Thromb Haemost. 2005, 3(3):531-40.
[2] Zuo P, et al. Circ J. 2015, 79(11):2499-508.

Synonyms

α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)

α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt

IC 851589

SR 90107A

Fondaparinux sodium

Arixtra

Xantidar

Fondaparin sodium

Org 31540

IC 85158

Fondaparinux

Fondaparin

Quixidar